Home  »  Companies   »  Merrimack Pharmaceuticals Inc. (MACK): Be Patient,...

Merrimack Pharmaceuticals Inc. (MACK): Be Patient, You Will Learn

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) concluded the trading at $11.90 on Wednesday, November 23 with a fall of -2.14% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $12.16 and 5Y monthly beta was reading 1.33 with its price kept floating in the range of $11.82 and $12.30 on the day. Considering stock’s 52-week price range provides that MACK hit a high price of $13.66 and saw its price falling to a low level of $3.00 during that period. Over a period of past 1-month, stock came adding 210.70% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review MACK stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 50% Buy for it.

According to ratings assigned by 2 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 1 of them are recommending Merrimack Pharmaceuticals Inc. (MACK) as a Hold, while 0 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the MACK stock which is currently positioned at 0. It further provides that stock’s current price level is 47.94% away from its 20-day simple moving average and is 116.92% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 78.39 while volatility remained at 3.48% over the past week which changes to 7.90% when measuring it over the past month. Beta is valued at 1.47, while measure of average true range or ATR is currently at 0.78.

In comparing Merrimack Pharmaceuticals Inc. (MACK)’s stock with other industry players reveals that stock’s current price change of -2.14% and that of 186.06% over the past 12 months is in competing position with that of Clovis Oncology Inc. (CLVS) which saw its stock price raised by 2.32% in the last trading and went through a decrease of -89.60% in past 12-month trading. Industry’s another major player Sanofi (SNY) has fall -0.02% down in previous session, but over the past year has faced a fall of -9.27%, while Madrigal Pharmaceuticals Inc. (MDGL) was also down -0.63% however its price remained floating in the red at -19.46% over the same period. Merrimack Pharmaceuticals Inc. has a P/E ratio of 0 while Sanofi is showing 17.09 for the same. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.

Having a second look at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) provides that stock’s average daily trading volume for 3 months was 623.69K, while it jumped to 3.91 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 13.41 million.

The percentage of outstanding shares held by the insiders is 1.09% while it is 65.00% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 0.26 million which implies a short ratio of 10.43. This shows up a 1.91% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 0.25 million in the previous month. Addition of 204.35% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *